MX2021005012A - Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr. - Google Patents

Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr.

Info

Publication number
MX2021005012A
MX2021005012A MX2021005012A MX2021005012A MX2021005012A MX 2021005012 A MX2021005012 A MX 2021005012A MX 2021005012 A MX2021005012 A MX 2021005012A MX 2021005012 A MX2021005012 A MX 2021005012A MX 2021005012 A MX2021005012 A MX 2021005012A
Authority
MX
Mexico
Prior art keywords
compounds
methods
pharmaceutical compositions
kinase inhibitors
atr kinase
Prior art date
Application number
MX2021005012A
Other languages
English (en)
Inventor
Lee Fader
Sheldon N Crane
Vouy Linh Truong
Abbas Abdoli
Jean- François TRUCHON
Cameron Black
Stéphane Dorich
Stéphanie Lanoix
Paul Jones
Miguel St-Onge
Audrey Picard
Cyrus M Lacbay
Original Assignee
Repare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repare Therapeutics Inc filed Critical Repare Therapeutics Inc
Publication of MX2021005012A publication Critical patent/MX2021005012A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

Se describen compuestos y sales farmacéuticamente aceptables de estos que se pueden usar en el tratamiento de sujetos que los necesitan. Los compuestos descritos en la presente pueden ser inhibidores de la proteína cinasa relacionada con ataxia telangiectasia y RAD3 (ATR). También se describen composiciones farmacéuticas que contienen los compuestos o sales farmacéuticamente aceptables de estos y métodos para su preparación y uso.
MX2021005012A 2018-10-30 2019-10-30 Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr. MX2021005012A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752873P 2018-10-30 2018-10-30
US201962877177P 2019-07-22 2019-07-22
PCT/CA2019/051539 WO2020087170A1 (en) 2018-10-30 2019-10-30 Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2021005012A true MX2021005012A (es) 2021-07-21

Family

ID=70461742

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005012A MX2021005012A (es) 2018-10-30 2019-10-30 Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr.

Country Status (16)

Country Link
US (1) US20210277002A1 (es)
EP (1) EP3873905A4 (es)
JP (1) JP2022510501A (es)
KR (1) KR20210097124A (es)
CN (1) CN113454080A (es)
AU (1) AU2019373416A1 (es)
BR (1) BR112021008336A2 (es)
CA (1) CA3118218A1 (es)
CR (1) CR20210281A (es)
EC (1) ECSP21038390A (es)
IL (1) IL282801A (es)
MA (1) MA54091A (es)
MX (1) MX2021005012A (es)
PH (1) PH12021550992A1 (es)
SG (1) SG11202104460UA (es)
WO (1) WO2020087170A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
MX2022007163A (es) * 2019-12-11 2022-08-25 Repare Therapeutics Inc Uso de inhibidores de atr en combinacion con inhibidores de parp.
TW202214642A (zh) * 2020-07-02 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 咪唑并嘧啶類衍生物、其製備方法及其在醫藥上的應用
WO2022028598A1 (en) * 2020-08-07 2022-02-10 Shanghai Antengene Corporation Limited Atr inhibitors and uses thereof
US20240043419A1 (en) * 2020-09-27 2024-02-08 Medshine Discovery Inc. Class of 1,7-naphthyridine compounds and application thereof
AU2022266856A1 (en) * 2021-04-28 2023-11-09 Repare Therapeutics Inc. Methods of treating cancers having a biallelic loss of function or gene overexpression mutation
BR112023024942A2 (pt) * 2021-06-16 2024-02-15 Repare Therapeutics Inc Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer
KR20240041354A (ko) 2021-07-27 2024-03-29 릿츠뜨 메디시네스 엘티디 8-옥소-3-아자비시클로[3.2.1]옥탄계 화합물 또는 이의 염 및 이의 제조 방법과 용도
WO2023016529A1 (zh) * 2021-08-11 2023-02-16 微境生物医药科技(上海)有限公司 作为atr抑制剂的萘啶衍生物及其制备方法
CN116262749A (zh) * 2021-12-15 2023-06-16 上海翊石医药科技有限公司 一类芳杂环取代的化合物及其制备方法和用途
WO2023193114A1 (en) * 2022-04-07 2023-10-12 Repare Therapeutics Inc. Methods of using atr inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3511330T3 (pl) * 2009-12-31 2021-04-19 Hutchison Medipharma Limited Syntetyczny związek pośredni użyteczny w wytwarzaniu triazolopirydynowych inhibitorów c-Met
WO2013039988A1 (en) * 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
WO2013067302A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013095761A1 (en) * 2011-12-20 2013-06-27 Glaxosmithkline Llc Imidazopyridine derivatives as pi3 kinase inhibitors
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
BR122023023802A2 (pt) * 2015-04-29 2023-12-26 Janssen Pharmaceutica Nv Compostos azabenzimidazóis, seu uso como moduladores do receptor de ampa e composições farmacêuticas que os compreendem
US10729680B2 (en) * 2016-01-14 2020-08-04 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines

Also Published As

Publication number Publication date
MA54091A (fr) 2021-09-15
BR112021008336A2 (pt) 2021-08-03
US20210277002A1 (en) 2021-09-09
AU2019373416A1 (en) 2021-06-10
CA3118218A1 (en) 2020-05-07
EP3873905A4 (en) 2022-08-17
IL282801A (en) 2021-06-30
CR20210281A (es) 2021-10-25
CN113454080A (zh) 2021-09-28
PH12021550992A1 (en) 2021-10-04
JP2022510501A (ja) 2022-01-26
KR20210097124A (ko) 2021-08-06
EP3873905A1 (en) 2021-09-08
WO2020087170A1 (en) 2020-05-07
SG11202104460UA (en) 2021-05-28
ECSP21038390A (es) 2021-08-31

Similar Documents

Publication Publication Date Title
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
MX2022012178A (es) Compuestos, composiciones farmaceuticas y metodos para la preparacion de compuestos y para su uso.
MX2019013954A (es) Inhibidores covalentes de kras.
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
PH12015502792A1 (en) Crystalline bromodomain inhibitors
MY187047A (en) Selective pyy compounds and uses thereof
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
WO2016109217A3 (en) Btk inhibitors
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
WO2016140933A3 (en) Immediate release soluble ibuprofen compositions
MX2016014701A (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
PH12018502139A1 (en) Phosphaplatin liquid formulations
PH12020551493A1 (en) Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors
EA201992303A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1